Evaluation of prognostic factors in stage IIA breast tumors and their correlation with mortality risk

Clinics

Volumn 66, Issue 4, 2011, Pages 607-612

  Carvalho, Solange Torchia ^a   Stiepcich, Monica Maria ^a   Fregnani, José Humberto ^a   Nonogaki, Sueli ^a   Rocha, Rafael ^a   Soares, Fernando Augusto ^a  

^a A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

Breast cancer; Immunohistochemistry; Molecular markers; Staging; Tissue microarray

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; PROGESTERONE RECEPTOR; TUMOR MARKER;

ARTICLE; BASAL CELL CARCINOMA; BREAST TUMOR; CANCER STAGING; CHEMISTRY; EPIDEMIOLOGY; FEMALE; HUMAN; MIDDLE AGED; MORTALITY; PATHOLOGY; PHENOTYPE; PROGNOSIS;

BREAST NEOPLASMS; CARCINOMA, BASAL CELL; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NITRIC OXIDE SYNTHASE TYPE II; PHENOTYPE; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 79958751923     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322011000400014     Document Type: Article

References (35)

1. Cãncer demama. Ministério da Saúde. Instituto Nacional do Cãncer. http://www1.inca.gov.br/estimativa/2009/index.asp?link=mapa.asp&ID=13.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin. 2009; 59:225-249, doi: 10.3322/caac.20006.
3. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005; 365: 1687-1717, doi: 10.1016/S0140-6736(05)66544-0.
4. Smigal C, Jemal A, Ward E, Cokkinides V, Smith R, Howe HL, et al. Trends in breast cancer by race and ethnicity: Update 2006. CA Cancer J Clin. 2006; 56: 168-183, doi: 10.3322/canjclin.56.3.168.
5. American cancer society. Cancer facts and figures. American Cancer Society. 2005. Atlanta.
6. Soerjomataram I, Louwman MW, Ribot JG, Roukema JA, Coebergh JW. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat. 2008; 107: 309-330, doi: 10.1007/s10549-007-9556-1.
7. Singletary SE, Connolly JL. Breast cancer staging: Working with the sixth edition of the ajcc cancer staging manual. CA Cancer J Clin. 2006; 56: 37-47, doi: 10.3322/canjclin.56.1.37.
8. Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the surveillance, epidemiology, and end results (seer) program. Oncologist. 2003;8:541-552, doi: 10.1634/theoncologist.8-6-541.
9. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752, doi: 10.1038/35021093.
10. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869-10874, doi: 10.1073/pnas.191367098.
11. Thompson EW, Newgreen DF, Tarin D. Carcinoma invasion and metastasis: A role for epithelial-mesenchymal transition? Cancer Res. 2005; 65: 5991-5995, doi: 10.1158/0008-5472.CAN-05-0616.
12. Come C, Magnino F, Bibeau F, De Santa Barbara P, Becker KF, Theillet C, et al. Snail and slug play distinct roles during breast carcinoma progression. Clin Cancer Res. 2006;12:5395-5402, doi: 10.1158/1078-0432.CCR-06-0478.
13. Thiery JP, Sleeman JP. Complex networks orchestrate epithelialmesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7:131-142, doi: 10.1038/nrm1835.
14. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Statistics Subcommittee of NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat. 2006;100:229-235, doi: 10.1007/s10549-006-9242-8.
15. Sobin LH, Wittekind C. International Union against Cancer. Tnm: Classification of malignant tumours. 6th edn. New York, Wiley-Liss, 2006.
16. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4:844-847, doi: 10.1038/nm0798-844.
17. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155-168.
18. Arriagada R, Le MG, Dunant A, Tubiana M, Contesso G. Twenty-five years of follow-up in patients with operable breast carcinoma: Correlation between clinicopathologic factors and the risk of death in each 5-year period. Cancer. 2006;106:743-750, doi: 10.1002/cncr.21659.
19. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the carolina breast cancer study. JAMA. 2006;295:2492-2502, doi: 10.1001/jama.295.21.2492.
20. Thomas JS, Kerr GR, Jack WJ, Campbell F, McKay L, Pedersen HC, et al. Histological grading of invasive breast carcinoma--a simplification of existing methods in a large conservation series with long-term follow-up. Histopathology. 2009;55:724-731, doi: 10.1111/j.1365-2559.2009.03429.x.
21. Fisher ER, Anderson S, Tan-Chiu E, Fisher B, Eaton L, Wolmark N. Fifteen-year prognostic discriminants for invasive breast carcinoma: National surgical adjuvant breast and bowel project protocol-06. Cancer. 2001;91: 1679-1687, doi: 10.1002/1097-0142(20010415)91:8+,1679::AIDCNCR1183.3.0.CO;2-8.
22. Warwick J, Tabar L, Vitak B, Duffy SW. Time-dependent effects on survival in breast carcinoma: Results of 20 years of follow-up from the swedish two-county study. Cancer. 2004;100:1331-1336, doi: 10.1002/cncr.20140.
23. Ellis IO, Elston CW. Tumors of the breast. In: Fletcher CDM Diagnostic histopathology of tumors. Churchill Livingstone, Edinburgh; New York; 1998.p 635-689.
24. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367-5374, doi: 10.1158/1078-0432.CCR-04-0220.
25. Zaha DC, Lazar E, Lazureanu C. Clinicopathologic features and five years survival analysis in molecular subtypes of breast cancer. Rom J Morphol Embryol. 2010;51:85-89.
26. Fernandes RC, Bevilacqua JL, Soares IC, Siqueira SA, Pires L, Hegg R, et al. Coordinated expression of er, pr and her2 define different prognostic subtypes among poorly differentiated breast carcinomas. Histopathology. 2009;55:346-352, doi: 10.1111/j.1365-2559.2009.03380.x.
27. van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol. 2002;161:1991-1996, doi: 10.1016/S0002-9440(10)64476-8.
28. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429-4434, doi: 10.1158/1078-0432.CCR-06-3045.
29. Reis-Filho JS, Tutt AN. Triple negative tumours: A critical review. Histopathology. 2008;52:108-118, doi: 10.1111/j.1365-2559.2007.02889.x.
30. Haupt B, Ro JY, Schwartz MR. Basal-like breast carcinoma: A phenotypically distinct entity. Arch Pathol Lab Med. 2010;134:130-133.
31. De Brot M, Soares FA, Stiepcich MM, Curcio VS, Gobbi H. Basal-like breast cancers: Clinicopathological features and outcome. Rev Assoc Med Bras. 2009;55:529-534, doi: 10.1590/S0104-42302009000500014.
32. Dutra MC, Rezende MA, de Andrade VP, Soares FA, Ribeiro MV, de Paula EC, et al. Immunophenotype and evolution of breast carcinomas: A comparison between very young and postmenopausal women. Rev Bras Ginecol Obstet. 2009;31:54-60, doi: 10.1590/S0100-72032009000200002.
33. Logullo AF, Nonogaki S, Pasini FS, Osorio CA, Soares FA, Brentani MM. Concomitant expression of epithelial-mesenchymal transition biomarkers in breast ductal carcinoma: Association with progression. Oncol Rep. 2010;23: 313-320.
34. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 2008;68:989-997, doi: 10.1158/0008-5472.CAN-07-2017.
35. Makdissi FB, Machado LV, Oliveira AG, Benvenuti TT, Katayama ML, Brentani MM, Osório CA, Mourão Netto M, Lyra EC, Carvalho F, Góes JC, Folgueira MA. Expression of E-cadherin, Snail and Hakai in epithelial cells isolated from the primary tumor and from peritumoral tissue of invasive ductal breast carcinomas. Braz J Med Biol Res. 2009;42:1128-1137, doi: 10.1590/S0100-879X2009007500010.